Cargando…

Brève : Avis positif pour l’UE du rappel bivalent Omicron BA.4/BA.5

Detalles Bibliográficos
Autor principal:	Dalmat, Yann-Mickael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595500/ http://dx.doi.org/10.1016/S0992-5945(22)00191-X

Ejemplares similares

Brèves : Test coronavirus français pour l’UE
por: Manus, Jean-Marie
Publicado: (2020)

Un vaccin anti-Covid-19 approuvé pour les 12-15 ans de l’UE
por: Dalmat, Yann-Mickael
Publicado: (2021)

Brève : Vaccin anti-Covid Janssen : quand le rappel n’est que la seconde dose
por: Dalmat, Yann-Mickael
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Brève : « Voyageurs, évitez Omicron », conseille l’OMS
por: Dalmat, Yann-Mickael
Publicado: (2022)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

Brève : Pourquoi un second rappel ?
por: Manus, Jean-Marie
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Brève : Covid-19 : un risque certain pour les ambulanciers
por: Dalmat, Yann-Mickael
Publicado: (2021)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Et de trois : l’UE recommande le vaccin AstraZeneca/Oxford
por: Manus, Jean-Marie
Publicado: (2021)

Bréve : AIDS2020/Conférence internationale du sida
por: Dalmat, Yann-Mickael
Publicado: (2020)

Brève : Vaccin Covid-19 : mesures pour agir contre la défiance
por: Dalmat, Yann-Mickael
Publicado: (2021)

Brève : Second rappel ou quatrième dose ?
por: Manus, Jean-Marie
Publicado: (2022)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Brève : Un vaccin Covid-19 indien sans aiguille pour l’Inde
por: Dalmat, Yann-Mickael
Publicado: (2021)

Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
por: Peled, Yael, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Brève : Disponibilité des tests de détection du Sars-CoV-2
por: Dalmat, Yann-Mickael
Publicado: (2021)

Brève : BioMérieux : marquage CE pour un test sérologique semi-quantitatif Sars-CoV-2
por: Dalmat, Yann-Mickael
Publicado: (2021)

Quel risque avec les sous-variants du virus Omicron ?
por: Dalmat, Yann-Mickael
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Quelques rappels pour la mise en route des differentes operations du AA
por: Rinolfi, L
Publicado: (1981)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Bréve: Chloroquine OTC : danger !
por: Dalmat, Yann-Mickael
Publicado: (2020)

Bréve : Chloroquine OTC : danger !
por: Dalmat, Yann-Mickael
Publicado: (2020)

Noninvasive Assessment of Arterial Stiffness Using Oscillometric Methods: baPWV, CAVI, API, and AVI
por: Miyata, Masaaki
Publicado: (2018)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
por: Moss, Stephen, et al.
Publicado: (2023)

Brève : Handicap mental, priorité vaccination
por: Dalmat, Yann-Mickael
Publicado: (2021)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7pdc7eh7h59nuhmfb7vt6ukb6r